Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
The U.S. Food and Drug Administration has approved three drugs for human use that contain active ingredients present in or similar to those in marijuana.
Marinol, Sydros, and Cesamet, and Zynerba Pharmaceuticals’ ZYN002 Gel should be delivering Phase II study results late this summer.
Phase I results for using ZYN002 Gel for patients with Fragile X Syndrome (FXS) are expected this summer.
Top-line Phase II results for studies involving using the gel on adult epilepsy and osteoarthritis in knees are projected to be ready in July or August 2017.
Synthetic cannabinoids are currently categorized as Schedule 1 substances because of their relationship with marijuana, but once they gain approval by the U.S. Food and Drug Administration (FDA), they will have a demonstrated medical benefit and will likely be re-categorized to a Schedule 3 or 4, or possibly de-scheduled entirely, according to Zynerba Pharmaceuticals CEO Armando Anido.
Right now there is no known cure for Fluoroquinolone Toxicity Syndrome, also known as Floxing.
However, medical marijuana high in THC has been shown help with pain, help repair damaged cells, and assist with sleep.
All of these happen to be essential for healing.
Stated legal cannabis sales in the U.S. in 2016 reached $6.7 billion.
The number was reported in a January 3, 2017, Archview Group press release.
This was a growth of 30 percent over the previous year.
Sales are projected to increase to $20.2 billion by the year 2021, representing a 25 percent compound annual growth rate.
Archview Market Research Editor-in-Chief, Tom Adams, stated:
“The biggest game changer for the future are the four new states that approved adult-use measures; 21 percent of the total US population now live in legal adult-use markets.”
He further stated that:
“Spending in the largest three adult-use markets (CO, WA, and OR) was up 62 percent through September after doubling in 2015. This was fueled in large part by the sudden popularity of alternative ingestion methods such as edibles and concentrates.”
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
According to the FDA, Zyno Medical issued a Class I recall on several of their infusion pumps after discovery of a potentially dangerous software malfunction. The company announced the recall on September 13th, 2024, notifying all users via an Urgent Medical Device Correction letter. The
Late last week, Youngstown Grape Distributors Inc. issued a voluntary recall of two lots of their Happy Moose Juice, citing a production error and an increased risk of bacterial contamination. The recall was initiated on October 4th, and the FDA shared the company’s announcement on
Philips Respironics, Inc. has issued an Urgent Medical Device Correction for their series of Trilogy Evo ventilators due to concerns of aerosol deposits on the flow sensor when using in-line nebulizers. According to the FDA, the correction involves a field safety notice with updated guidelines